Gene Therapy Milestones

Vol. 19, Suppl. 1, 1996 

---

Article (PDF 1621 KB)

---

Oncogene Expression in Multidrug-Resistant Ovarian Carcinomas

Lu Jiao^a, Lucy Xia^a, Mark Horng^a, Brandon Kashfian^a, Mohammed Kashani-Sabet^b, Kevin J. Scanlon^a

^aSection of Biochemical Pharmacology, Department of Medical Oncology, City of Hope Medical Center, Duarte, Calif., and
^bDermatology Department, University of California, San Francisco, Calif., USA

Address of Corresponding Author

Onkologie 1996;19 (Suppl. 1):19-22 (DOI: 10.1159/000218882)

---

 Key Words

• Cisplatin
• Actinomycin D
• Multidrug resistance
• Oncogenes
• p53

---

 Summary

Proto-oncogenes have been shown to play a critical role in cell growth and differentiation via signal transduction pathways. Oncogenes, either by enhanced gene expression or altered gene expression, can trigger cellular transformation. In this study, the role of oncogenes was defined in drug-resistant human ovarian carcinoma cells. In both multidrug resistant (actinomycin D) cells and non-multidrug-resistant (cisplatin) cells, Northern analyses demonstrated enhanced gene expression for the following oncogenes: c-fos, c-jun, H-ras, and p53. Based on these findings, strategies are discussed for the use of ribozymes, catalytic RNAs, to suppress gene expression and reverse the observed drug resistance.

Copyright © 1996 S. Karger AG, Basel

---

 Author Contacts

Dr. Kevin J. Scanlon, Section of Biochemical Pharmacology, Department of Medical Oncology, City of Hope Medical Center, Montana Bldg. 1500 E. Duarte Road, Duarte, CA 91010 (USA)

---

 Article Information

Published online: May 12, 2009
Number of Print Pages : 4

Lu Jiao
Lucy Xia
Brandon Kashfian
Mark Horng
Mohammed Kashani-Sabet
Kevin J. Scanlon